Quantum Genesis AI (QGAI) Stock Overview
A biotransformation company, focuses on advancing enzyme-based solutions for pharmaceutical manufacturing. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
QGAI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Quantum Genesis AI Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$5.04 |
| 52 Week Low | US$0.0025 |
| Beta | 24.56 |
| 1 Month Change | -82.61% |
| 3 Month Change | -70.80% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -60.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| QGAI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -92.1% | 1.3% | -0.7% |
| 1Y | n/a | 27.4% | 11.4% |
Return vs Industry: Insufficient data to determine how QGAI performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how QGAI performed against the US Market.
Price Volatility
| QGAI volatility | |
|---|---|
| QGAI Average Weekly Movement | 57.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: QGAI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QGAI's weekly volatility has decreased from 962% to 57% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Naveen Kulkarni | www.quantumzymecorp.com |
Quantum Genesis AI Corp., a biotransformation company, focuses on advancing enzyme-based solutions for pharmaceutical manufacturing. It utilizes customer centric research to enhance enzyme activity, by applying quantum mechanics, molecular modelling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts designed to enhance efficiency, reduce waste, and support production. The company was formerly known as Quantumzyme Corp. and changed its name to Quantum Genesis AI Corp. in February 2026.
Quantum Genesis AI Corp. Fundamentals Summary
| QGAI fundamental statistics | |
|---|---|
| Market cap | US$32.78m |
| Earnings (TTM) | -US$183.61k |
| Revenue (TTM) | n/a |
Is QGAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QGAI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$183.61k |
| Earnings | -US$183.61k |
Last Reported Earnings
Oct 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0045 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -54.7% |
How did QGAI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/18 15:09 |
| End of Day Share Price | 2026/02/18 00:00 |
| Earnings | 2025/10/31 |
| Annual Earnings | 2025/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Quantum Genesis AI Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.